We are pleased to announce that we now accept all major credit cards, as well as HSA and FSA for payment!
Low libido refers to a decrease in sexual interest, thoughts, or desire for intimacy. Sexual desire naturally varies throughout life, and there is no single amount of interest that is considered normal for every person.
Some women experience spontaneous desire, while others notice that interest develops only after affectionate touch or sexual activity has already begun. ACOG recognizes that desire does not always need to occur before arousal or intimacy.
A change becomes more concerning when it is persistent, noticeably different from a woman’s previous experience, causes personal distress, or affects her well-being or relationships.
Optimal Female Wellness provides individualized evaluation to help determine what may be affecting sexual desire and which treatment options may be appropriate.
Sexual desire is influenced by biological, psychological, interpersonal, and social factors.
Possible contributors include:
More than one factor may be present at the same time.
A woman experiencing night sweats, poor sleep, vaginal discomfort, and increased stress may notice less interest in intimacy even though no single hormone abnormality explains the change.
Sexual health can change during the menopause transition.
Lower and fluctuating estrogen levels may occur alongside:
ACOG notes that declining estrogen around menopause can cause thinning, dryness, and inflammation of vaginal tissues. These changes may make intercourse painful.
The combination can affect desire indirectly.
For example, someone who expects intimacy to hurt may become less interested in initiating it. A woman who is sleeping poorly because of night sweats may have little energy for sexual activity.
Menopause may therefore contribute to low libido without there being a single “low libido hormone” that needs to be replaced.
During perimenopause and menopause, lower estrogen levels may affect the vulva, vagina, bladder, and urinary tract.
This group of changes is known as genitourinary syndrome of menopause, or GSM.
Symptoms may include:
ACOG identifies vaginal dryness, pain with sex, bladder concerns, burning, itching, and irritation as possible symptoms of GSM.
Treating these symptoms may improve comfort and make sexual activity more appealing.
Options may include lubricants, vaginal moisturizers, vaginal estrogen, or other prescription treatment depending on the patient’s symptoms and health history.
Low desire does not necessarily mean something is medically wrong with either partner.
Sexual interest may be affected by:
These factors should be discussed without assigning blame.
A medication cannot resolve every source of low desire. When relationship or communication concerns play an important role, couples counseling or a qualified sexual-health therapist may be more useful than medication alone.
Evaluation begins with a confidential discussion rather than a laboratory number.
Topics may include:
It is also helpful to determine whether low desire occurs in every situation or only under certain circumstances.
A clinician may ask whether the patient still experiences sexual thoughts, responds to affectionate touch, enjoys intimacy after it begins, or avoids sex because of discomfort.
The goal is to understand the complete pattern rather than reduce libido to one hormone value.
Hormone testing is not automatically required for every woman experiencing low desire.
Testing may be appropriate when symptoms suggest:
Other laboratory testing may be considered when fatigue, anemia, metabolic conditions, or another health problem could be contributing.
A single testosterone result does not diagnose HSDD.
Testosterone levels can be useful when testosterone treatment is being considered, particularly to establish a baseline and help prevent excessive dosing, but treatment should not be prescribed merely to raise a laboratory number.
When intimacy hurts, treating the discomfort often becomes the priority.
Depending on the cause, treatment may include:
ACOG recommends medical evaluation for frequent or severe pain during sex because gynecologic conditions may need to be ruled out.
Repeated painful experiences can create anticipation of pain, muscle tension, anxiety, and further avoidance.
Increasing sexual desire without treating the pain would not resolve that cycle.
Prescription medication may be considered for some patients with carefully evaluated HSDD.
Medication does not act as an instant sexual stimulant and should not be used simply to enhance sexual performance.
They are different medications with different eligibility criteria, dosing schedules, side effects, and precautions.
A complete medication and health review is necessary before either is considered.
Flibanserin, sold under the brand name Addyi, is a daily oral prescription medication.
Importantly, its FDA indication has changed from earlier labeling.
The current FDA label indicates flibanserin for women younger than age 65 with acquired, generalized HSDD when the low sexual desire causes marked distress or interpersonal difficulty and is not caused by another medical or psychiatric condition, a relationship problem, or medication or substance use.
This means it is no longer accurate to describe flibanserin as an option only for premenopausal women.
Flibanserin is taken regularly rather than immediately before sexual activity.
Possible side effects include:
Medication interactions, alcohol use, liver health, and other prescriptions require careful review.
It is not intended to enhance sexual performance.
Testosterone therapy is sometimes considered off-label for carefully selected women with HSDD, particularly after menopause.
An international evidence-based consensus concluded that the primary evidence-supported indication for testosterone therapy in women is HSDD after an appropriate biopsychosocial assessment.
However, there is currently no testosterone product specifically FDA-approved in the United States for treating HSDD in women.
Treatment requires careful dosing because products formulated for men may deliver substantially more testosterone than is appropriate for a woman.
Potential androgen-related side effects include:
Excessive exposure may create additional androgen-related effects.
Long-term safety data remain more limited than short-term data, so treatment requires appropriate monitoring.
Testosterone should not be prescribed simply because a laboratory value appears low.
It also should not be promoted as a general treatment for fatigue, brain fog, weight loss, or anti-aging.
Desire often changes during pregnancy and after childbirth.
Possible contributors include:
Lower estrogen levels during breastfeeding may contribute to vaginal dryness.
These changes may be temporary and do not automatically indicate a sexual-desire disorder.
Medication and hormone treatment options also require additional reproductive-safety considerations during pregnancy and breastfeeding.
Patients should discuss pregnancy plans and contraception before beginning prescription libido treatment.
Changes in sexual desire are common and can be difficult to discuss, but sexual health is part of overall health. Low libido may be related to menopause symptoms, pain, medication effects, sleep, stress, mood, relationship factors, or several concerns occurring together.
Optimal Female Wellness provides individualized evaluation for persistent low sexual desire and related symptoms.
Schedule an appointment to discuss what has changed, whether vaginal or sexual discomfort is present, your current medications, menopause symptoms, and whether medication, hormone support, symptom treatment, or another approach may be appropriate.
Possible causes include menopause symptoms, vaginal dryness, painful sex, poor sleep, stress, depression, anxiety, thyroid disease, medication effects, relationship concerns, chronic illness, pregnancy, and breastfeeding.
No. Sexual desire naturally differs between people and changes throughout life. It becomes more clinically significant when the change is persistent, causes distress, and is not better explained by another concern.
Responsive desire means sexual interest develops after affectionate or sexual activity has begun rather than appearing spontaneously beforehand. This can be a normal pattern.
Hypoactive sexual desire disorder involves persistently low sexual desire that causes significant distress and is not primarily explained by another medical or psychiatric condition, medication, relationship issue, or substance.
Yes. Flibanserin is currently FDA-approved for women younger than 65 with qualifying acquired, generalized HSDD. Bremelanotide is approved for qualifying premenopausal women with acquired, generalized HSDD.
Yes. Menopause may contribute through vaginal dryness, pain during sex, hot flashes, poor sleep, mood changes, and other physical or emotional changes.
Estrogen is not specifically a libido medication. It may improve vaginal comfort, hot flashes, or sleep problems that are interfering with sexual interest.
Testosterone may be considered off-label for carefully selected women with HSDD, particularly after menopause. There is no FDA-approved testosterone product specifically for female HSDD in the United States, and treatment requires monitoring.
Yes. Some antidepressants, particularly SSRIs, may affect desire, arousal, or orgasm. Medication should not be stopped abruptly; symptoms and possible alternatives should be discussed with the prescribing clinician.
Consider an evaluation when reduced desire persists, causes personal distress, affects a relationship, or occurs with pain, vaginal dryness, bleeding, fatigue, mood changes, menopause symptoms, or other health concerns.